Press Releases Items Per Page 102550 Year None202220212020201920182017201620152014 09-15-2022 Daré Bioscience to Participate in Two Upcoming Conferences 09-06-2022 Daré Bioscience to Participate in H.C. Wainwright 24th Annual Global Investment Conference 08-29-2022 Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder 08-24-2022 Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health 08-09-2022 Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update 08-02-2022 Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022 07-07-2022 Daré Bioscience to Participate in Maxim Group Women’s Health Panel 06-30-2022 Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis 06-24-2022 Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022 06-06-2022 Daré Bioscience to Participate in the 2022 BIO International Convention Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 23
09-06-2022 Daré Bioscience to Participate in H.C. Wainwright 24th Annual Global Investment Conference
08-29-2022 Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
08-24-2022 Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health
08-09-2022 Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update
08-02-2022 Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022
06-30-2022 Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis
06-24-2022 Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022
